Form 4: Verastem CFO Sells Shares to Cover Tax Obligations from RSU Vesting

Verastem, Inc.'s Chief Financial Officer, Daniel Calkins, reported the sale of company common stock totaling 4,135 shares in June 2025, primarily to satisfy tax withholding requirements related to restricted stock unit vesting.

Summary

• Daniel Calkins, Chief Financial Officer of Verastem, Inc. (VSTM), reported two sales of common stock.
• On June 20, 2025, Mr. Calkins sold 4,110 shares at a price of $5.13 per share.
• On June 23, 2025, an additional 25 shares were sold at $4.71 per share.
• The total number of shares sold across both transactions was 4,135.
• Following these transactions, Mr. Calkins beneficially owns 109,920 shares of Verastem common stock.
• The sales were conducted to satisfy statutory withholding requirements in connection with the vesting of restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it reports a sale of shares by an insider, the explicit reason provided (to cover tax obligations from RSU vesting) indicates a non-discretionary transaction related to compensation, which is a routine and expected event rather than a signal of negative sentiment towards the company.

Positives

• The sales were not discretionary but rather to cover statutory withholding requirements related to the vesting of restricted stock units, indicating that the CFO received equity compensation.
• The vesting of restricted stock units suggests ongoing compensation and retention of key management.

Negatives

• A reduction in insider ownership, although explained as non-discretionary, can sometimes be perceived negatively by the market.

Future Outlook

NA

Management Comments

• "The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units."

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction, common across all publicly traded companies, and does not provide specific insights into broader industry trends or competitive dynamics within the biotechnology or pharmaceutical sector where Verastem operates.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Minor, as the sale is routine for tax purposes and not indicative of a change in management's confidence or strategy.
• Employees: No direct impact, but it highlights the company's use of equity compensation (RSUs) for executives.

Key Dates

Keywords

Verastem, VSTM, Daniel Calkins, Chief Financial Officer, CFO, Form 4, SEC filing, insider transaction, stock sale, restricted stock units, RSU, equity compensation, tax withholding